TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pituitary and gonadal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Iron level measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically relevant improvement in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome difference
Endpoint domain: Adverse events/effects
Primary endpoint: Global cognitive function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dementia and cerebrovascular events incidence
Endpoint domain: Mortality/survival
Primary endpoint: Safety of high dose Colistin
Endpoint domain: Adverse events/effects
Primary endpoint: heart failure hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: time to death or hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With an Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of MVA85A
Endpoint domain: Adverse events/effects
Primary endpoint: Dementia diagnosis criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of lumpectomy cavity seroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of anti-ttg-m for diagnosis of celiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of anti-ttg-m in the control group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Vessel Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angular deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LRA success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in drinking behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrimination of Benign Disease and Malignant Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Speech, Spatial and Qualities of Hearing (SSQ) scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: onset of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriateness of intravenous antibiotics prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in number of passes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of dominant follicles (≥13 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total number of oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in baseline of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripartum hysterectomy rate
Endpoint domain: Mortality/survival
Primary endpoint: Depression Evaluation using PHQ-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety Evaluation using GAD-7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful labor induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline in Mean Minnesota Living With Heart Failure Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Mean Score of Physical Component of the SF-36 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Acute kidney injury stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Anti-drug Antibodies (ADAs) Against RO6895882
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in a global relief at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in frequency and type of stools at 4 weeks from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in severity and frequency of IBS-Intestinal discomfort symptoms at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Metabolic fuel utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of tivozanib
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of inflammation in the rectosigmoid epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peri-implantitis prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in active time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in sedentary time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in performance in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nasal Congestion Symptom Score (NCSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid parameters efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Understanding of endoscopy procedure recommendation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of benefits and risks of endoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patent ductus arteriosus (PDA) closure documented via echocardiogram by 36-weeks postmenstrual age (PMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality or supplemental oxygen or positive-pressure respiratory support at 36-weeks PMA
Endpoint domain: Mortality/survival
Primary endpoint: Composite Bayley III Motor Score at 22-26 months corrected age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intracompartmental pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response in patients with High Risk AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Facial muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of glucose values 71-180 mg/dL of combined day and night readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall frequency of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Overall frequency of hyperglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Daily Stool Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the semaglutide plasma concentration curve from 0 to tz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum semaglutide plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Global Tic Severity rating Scale (YGTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct size (total late enhancement volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with Modified Rankin Scale (mRS) less than or equal to 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patient eyes with an Intraocular Inflammation (IOI) event
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in richness of the microbial flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in evenness of distribution of the microbial flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with improved catheter contact force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with sufficiently increased tumoral iodine incorporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC0-inf for ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t for ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in linear measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in angular measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular alterations in breast cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean abundance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neck Disability Index (NDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Date of maximum apoptosis in prostate tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Elbow Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Elbow Function evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 2-year disease-free survival (DFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of moderate, severe, or life-threatening diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Change of urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of fecal egg counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in walking ability at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking efficiency at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax - Maximum Observed Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf - Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time-interval-weighted sum of pain relief (TOTPAR) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean steps/day count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Loneliness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurement of Hopelessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Appetite assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse limb events (MALE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in parent-reported infant sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in infant sleep efficacy
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Diameter of AVF outflow vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Blood flow through AVF outflow vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pregnancy-related low back and/or pelvic girdle pain (PPGP) during third gestational trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pregnancy-related low back and/or pelvic girdle pain (PPGP) at six weeks postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pregnancy-related low back and/or pelvic girdle pain (PPGP) at six months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postural control during first gestational trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural control during third gestational trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral nerve conduction latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Technical magnet placement success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of all adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in WOMAC A1 pain subscore (walking pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anal fissure pain measured by Visual Analog Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major structural birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 6-month Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Aerobic Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-Related Quality of Life: MLHFQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depth of infantile hemangioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Number of Spikes Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Preference for Gonal-f (FbM) Pen over vials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: closure of fistula at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically measured abnormality of laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: Average Proportion of Days of Any App Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Proportion of Days of HIV Medication Tracked
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Intervention Acceptability CSQ-8 Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Intervention Acceptability Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Saint-Georges questionnaire, item Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MMRC Dyspnea scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in 28 Joint Disease Activity Score (DAS28-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline of hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound Skills Assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correlation between 68Ga-FAPI PET uptake intensity and histopathologic FAP expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of psychiatric comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of On Time Without Dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Macular Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score during intravenous cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in whole-body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of volunteers with acute mountain sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and types of vaccines administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unmet vaccination needs identified and met
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of times the pharmacist reviewed the vaccination forecast and educated the patient on his/her vaccine needs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic yield of screening breast MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Achieving Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional performance probability P(n)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Definitive HIV infection in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of cancer metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Symptoms as measured by SNOT 22 questionnaire and visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Olfactory function as measured by Sniffin'Sticks 12 tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nasal patency as measured by Acoustic rhinometry and Rhinomanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Nasal endoscopy findings as measured by Lund-Kennedy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in radiographic fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neuromotor capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Marginal Adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Anatomic Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Forearm Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with good accordance with ENVU tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to achieve full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Atherosclerotic cardiovascular disease (ASCVD) 10-year risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vestibular evaluation DHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vestibular evaluation AAO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of intestinal microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional result
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiological result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of vorinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxic effects of vorinostat and cisplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Wheal diameter from morphine skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes